United Therapeutics jumped 12.5% on September 30, and BTIG has now stepped in with a Buy rating and a $728 price target. That arrival flips the analyst narrative: one day after a bearish Goldman initiation dominated the conversation, a fresh bull has entered with a target 34% above the current price of $541.89.
BTIG's upgrade, published October 1 by analyst Julian Harrison, sets a $728 target. Goldman Sachs, which initiated at Sell just a week ago with a $321 target, sits at the opposite extreme. The gap between the two new entrants is $407. Existing bulls have not moved: RBC Capital holds Outperform at $677, JP Morgan holds Overweight at $687, and Wells Fargo holds Overweight at $738. The consensus rating remains Hold, with two Hold ratings recorded as of September 30. The bull case for United Therapeutics rests on its dominant position in the prostacyclin pathway for pulmonary arterial hypertension and its pipeline of new indications. Bears, including Goldman, point to uncertainty around Tyvaso's expansion into IPF and competitive pressure.
Short interest climbed 13.9% over the past week to 6.21% of free float. That is a meaningful move, and the direction has been consistent. One month ago SI stood at a similar level, but the week-on-week acceleration is the notable shift. Despite that build, the borrow market is not stressed. Availability stands at 3,397%, meaning there are roughly 34 shares available to borrow for every one already borrowed. Cost to borrow has fallen to 0.27%, down 20% over the past week and 37% over the past month. Shorts are building positions into a very easy lending environment. The shorts are not scrambling for stock.
Wikipedia views and ORTEX stock page traffic for United Therapeutics hit 2.88 standard deviations above the company's own 90-day average as of September 27. That is an attention signal, not a revenue or earnings indicator. It measures public interest in the name, and the reading coincided with the Goldman initiation and the subsequent price move.
ORTEX Alt Data covering Centers for Medicare and Medicaid Services figures shows Medicaid prescriptions for United Therapeutics products have fallen for three consecutive quarters, most recently to 5,208 prescriptions in Q1 2026. Medicaid dollars reimbursed were down 11% on the same quarter a year earlier. These datasets have not been measured as leading indicators for United Therapeutics' reported figures, so they provide context rather than a directional signal on the October 28 earnings print.
See the live data behind this article on ORTEX.
Open UTHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
